Johnson & Johnson Talc Settlement Proposed

Johnson & Johnson said on July 27, 2026, it reached a proposed resolution to address its remaining U.S. talc litigation, a step that could substantially reduce long-running legal uncertainty for investors if courts and claimants approve.

Settlement Terms and Litigation Context

The company announced a conditional agreement committing up to $5.5 billion to resolve its remaining U.S. ovarian talc litigation. The deal requires participation by lead plaintiff firms and enrollment of at least 95% of the remaining claims. Payments will be spread over multiple years starting in 2027, with no more than $3 billion payable that year and no additional payments due before 2028. Johnson & Johnson described the proposed resolution as an efficient conclusion to the talc litigation. The agreement applies only to existing claims and does not cover future lawsuits.

Plaintiff-side summaries describe a negotiation framework expected to provide at least the company’s figure to roughly 70,000 claimants in the federal multidistrict litigation (MDL) and related state proceedings, allocating compensation via a tiered grid.

Legal summaries and trade reports estimate about 76,000 remaining U.S. talc claims, including roughly 69,000 consolidated in the federal MDL in New Jersey. The proposed resolution must be approved by the federal MDL court overseeing MDL No. 2738. If the participation threshold and court approval are met, the deal would resolve approximately 99.75% of remaining U.S. talc claims.

A July 22, 2026, ruling by U.S. Magistrate Judge Rukhsanah Singh required plaintiffs in the MDL to present admissible expert evidence linking talc use to individual ovarian cancers or face dismissal. Parties cited this order as part of the settlement backdrop.

Johnson & Johnson previously pursued three Chapter 11 bankruptcy strategies to resolve talc liabilities, all rejected by courts. After a bankruptcy dismissal in March 2025, ovarian cancer claims resumed, and juries returned multiple verdicts totaling more than $2.5 billion in late 2025.

Plaintiffs allege Johnson & Johnson’s talc products, including baby powder, were contaminated with asbestos and caused ovarian cancer, mesothelioma, and other illnesses. The company denies its talc products cause cancer or contain asbestos, citing prior rulings that narrowed plaintiffs’ proof on specific causation.

The settlement does not cover litigation outside the U.S., including about 7,000 potential claimants in the U.K.

Johnson & Johnson said the proposed resolution “constitutes an efficient conclusion to the talc litigation.”